Pharmaceuticals News and Research

RSS

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced dosing of the first patients enrolled in the Company's Phase 2b study of PG324, a novel, fixed-combination of Aerie's AR-13324 and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.

31 Jan 2014

YODA Project enters an agreement with Johnson & Johnson to gain access to clinical trial data assets

In a move that promotes open science, the Yale University Open Data Access (YODA) Project has entered an agreement with Johnson & Johnson that will enable scientists around the world to gain access to the company's clinical trial data assets.

30 Jan 2014

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2013. For the three months ended December 31, 2013, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported net product sales of Soliris® (eculizumab) of $441.9 million, compared to $320.5 million for the same period in 2012.

30 Jan 2014

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.

30 Jan 2014

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.

30 Jan 2014

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins.

30 Jan 2014

University of Liverpool receives funding to continue reducing impact of adverse reactions to medicinal drugs

The Medical Research Council (MRC) Centre for Drug Safety Science at the University of Liverpool has received three million pounds of new funding from MRC to allow it to continue reducing the impact of adverse reactions to medicinal drugs.

30 Jan 2014

Johnson & Johnson enters into novel agreement with YODA to share clinical trials data

Johnson & Johnson today announced that its subsidiary, Janssen Research and Development, LLC, has entered into a novel agreement with Yale School of Medicine's Open Data Access (YODA) Project that will extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine.

30 Jan 2014

Study details about healthful compounds contained in hempseed

Long stigmatized because of its "high"-inducing cousins, hemp - derived from low-hallucinogenic varieties of cannabis - is making a comeback, not just as a source of fiber for textiles, but also as a crop packed with oils that have potential health benefits.

30 Jan 2014

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine).

30 Jan 2014

Researchers design semi-synthetic proteins to analyse body's vital signal processes

Proteins play a fundamental role in almost all biological processes. They consist of chains constructed of up to 20 different amino acids, and their composition, structure and function are controlled by the genetic code.

29 Jan 2014

NPS MedicineWise urges health professionals to take the pledge to fight antibiotic resistance

NPS MedicineWise is urging all health professionals to take the pledge to fight antibiotic resistance after new research shows that making a public commitment leads to significant improvements in antibiotic prescribing.

29 Jan 2014

CU receives cooperative agreement to develop technological system to determine effects chemical agents

The University of Colorado Boulder has been awarded a cooperative agreement worth up to $14.6 million from the Defense Advanced Research Projects Agency (DARPA) to develop a new technological system to rapidly determine how drugs and biological or chemical agents exert their effects on human cells.

29 Jan 2014

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company's supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE.

28 Jan 2014

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years.

28 Jan 2014

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company's ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014.

28 Jan 2014

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced the FDA acceptance of its New Drug Application (NDA) for its lead product candidate, MPI-2505, a subcutaneous injectable methotrexate (MTX) in a ready-to-use injection device, for which the proposed indications are rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis.

28 Jan 2014

Intelsius introduces revisions to PharmaTherm line of solutions

Intelsius, a DGP company, a designer, manufacturer and distributor of temperature-controlled packaging solutions, introduced revisions to its PharmaTherm™ line of solutions to pharmaceutical industry professionals today at the 13th Annual Cool Chain Europe Summit in Luxembourg.

28 Jan 2014

Seward highlights effectiveness of Stomacher technique and sponge swabs for hygiene monitoring

Seward Ltd., manufacturers of the world leading range of Stomacher paddle blenders and Stomacher® accessories used in sample preparation for microbiological analyses, have highlighted the highly effective use of its Stomacher technology in combination with sponge swabs for hygiene monitoring and biosecurity applications.

28 Jan 2014

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

Scientists have begun the first human clinical trial of EDP-788, an investigational oral antibiotic intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections.

27 Jan 2014

Pharmaceuticals News and Research

Aerie Pharmaceuticals announces dosing of first patients in PG324 Phase 2b study

YODA Project enters an agreement with Johnson & Johnson to gain access to clinical trial data assets

Alexion Pharmaceuticals reports full year 2013 GAAP and non-GAAP financial results

Oramed Pharmaceuticals' ORMD-0801 Phase 2a study meets primary and secondary endpoints

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

University of Liverpool receives funding to continue reducing impact of adverse reactions to medicinal drugs

Johnson & Johnson enters into novel agreement with YODA to share clinical trials data

Study details about healthful compounds contained in hempseed

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Researchers design semi-synthetic proteins to analyse body's vital signal processes

NPS MedicineWise urges health professionals to take the pledge to fight antibiotic resistance

CU receives cooperative agreement to develop technological system to determine effects chemical agents

FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL

Curie-Cancer, Servier renew partnership to identify new therapeutic targets for triple negative breast cancer

Oramed to publish results of Phase 2a clinical trial for oral insulin capsule for treatment of type 2 diabetes

Medac Pharma announces FDA acceptance of New Drug Application for MPI-2505

Intelsius introduces revisions to PharmaTherm line of solutions

Seward highlights effectiveness of Stomacher technique and sponge swabs for hygiene monitoring

Scientists start clinical trial of EDP-788 oral antibiotic to treat MRSA infections

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence